The normal range of HbA1c for diabetic patients is not a single fixed figure — NICE guidelines set individualised targets based on treatment type, risk of hypoglycaemia, and personal circumstances. In the UK, HbA1c is measured in mmol/mol and serves as the cornerstone of long-term glucose monitoring, reflecting average blood glucose over the preceding 8 to 12 weeks. Understanding what your target means, what can skew the result, and how to act on an out-of-range reading is essential for reducing the risk of serious diabetes complications. This article explains the key thresholds, influencing factors, and NHS management options.

What Is HbA1c and Why It Matters in Diabetes

HbA1c measures the proportion of glycated haemoglobin in the blood, reflecting average glucose control over 8–12 weeks. NICE targets are 48 mmol/mol for most type 2 diabetes patients and 48 mmol/mol for type 1 diabetes, adjusted individually.

HbA1c, or glycated haemoglobin, is a blood test that reflects your average blood glucose levels over the preceding two to three months. When glucose circulates in the bloodstream, it attaches to haemoglobin — the protein found inside red blood cells. The higher your blood glucose over time, the greater the proportion of haemoglobin that becomes glycated. Because red blood cells live for approximately 120 days, the HbA1c result provides a reliable snapshot of longer-term glucose control — broadly reflecting the preceding 8 to 12 weeks — rather than a single moment in time.

In the UK, HbA1c is measured in millimoles per mole (mmol/mol), following international standardisation. For people without diabetes, a normal HbA1c is generally below 42 mmol/mol. A reading between 42 and 47 mmol/mol indicates non-diabetic hyperglycaemia (sometimes called a high risk of type 2 diabetes), whilst a result of 48 mmol/mol or above may be used diagnostically for type 2 diabetes in the appropriate clinical context. In asymptomatic adults, a diagnostic HbA1c of 48 mmol/mol or above should be confirmed with a repeat test before a diagnosis is made.

Important diagnostic caveats: HbA1c is not suitable for diagnosing diabetes in people with suspected type 1 diabetes, children and young people, during pregnancy, or where rapid-onset diabetes is suspected. In these situations, plasma glucose testing and urgent clinical referral are used instead.

For people already living with diabetes, NICE guidelines set individualised targets rather than a single universal figure. The broadly recommended targets are:

• 48 mmol/mol (6.5%) for most adults with type 2 diabetes managed by lifestyle or a single non-hypoglycaemic drug

• 53 mmol/mol (7.0%) for those on medications that carry a risk of hypoglycaemia, such as sulphonylureas or insulin

• For type 1 diabetes, NICE (NG17) recommends aiming for 48 mmol/mol, though individual targets are agreed between the patient and their clinical team

Regular HbA1c monitoring is a cornerstone of diabetes management in NHS practice. For those with suboptimal control or following a treatment change, testing is typically recommended every 3 to 6 months; once stable, testing should occur at least every 6 months. This helps to reduce the risk of long-term complications such as retinopathy, nephropathy, and cardiovascular disease.

Factors That Can Affect Your HbA1c Reading

Conditions affecting red blood cell lifespan — including haemolytic anaemia, iron deficiency, and chronic kidney disease — can falsely raise or lower HbA1c independently of actual glucose control. Haemoglobin variants and recent blood transfusions can also produce unreliable results.

Whilst HbA1c is a highly useful clinical tool, several physiological and medical factors can influence the result, sometimes independently of actual blood glucose control. Being aware of these variables helps both patients and clinicians interpret results accurately and avoid unnecessary changes to treatment.

Conditions affecting red blood cell turnover are among the most clinically significant confounders. Because HbA1c reflects glucose attachment over the lifespan of red blood cells, anything that shortens or lengthens that lifespan will alter the reading:

• Haemolytic anaemia or recent blood transfusion can falsely lower HbA1c by increasing red cell turnover or introducing donor cells

• Iron-deficiency anaemia, vitamin B12 deficiency, or folate deficiency can falsely raise HbA1c by prolonging red cell lifespan; levels typically fall once the deficiency is corrected

• Haemoglobin variants such as sickle cell trait or haemoglobin C can interfere with certain laboratory assays, producing unreliable readings — if a variant is suspected, your clinical team should liaise with the local laboratory to confirm which assay method is appropriate

Following a blood transfusion, HbA1c results may be unreliable for up to two to three months depending on the volume transfused; your clinical team will advise on alternative monitoring during this period.

Chronic kidney disease (CKD) can affect HbA1c in unpredictable ways. Shortened red cell survival in CKD may lower the result, whilst assay interference from carbamylated haemoglobin can raise it. The net effect is variable, and clinical correlation alongside alternative monitoring methods — such as capillary blood glucose profiles or continuous glucose monitoring (CGM) — is advisable.

Pregnancy brings physiological changes that make HbA1c unreliable as a primary monitoring tool. In line with NICE NG3, capillary blood glucose profiles and CGM are the preferred monitoring approaches during pregnancy; fructosamine may be considered only when HbA1c is uninterpretable.

Certain medications can also have an indirect effect. Corticosteroids such as prednisolone are well known to raise blood glucose levels, which will in turn elevate HbA1c over time. Conversely, erythropoiesis-stimulating agents used in renal anaemia may lower HbA1c by increasing red cell turnover.

If your clinical team suspects a falsely abnormal HbA1c, they may request alternative tests such as fructosamine (reflecting approximately two to three weeks of glucose control) or arrange CGM to build a more complete picture.

What Happens If Your HbA1c Is Outside the Target Range

A raised HbA1c increases the risk of microvascular and macrovascular complications, whilst a low result may indicate recurrent hypoglycaemia, particularly in those on insulin or sulphonylureas. Clinical review and possible treatment adjustment are recommended in both cases.

When HbA1c falls outside the agreed target range, it signals that blood glucose management may need to be reviewed — though the appropriate clinical response depends on whether the result is higher or lower than the target, and by how much.

A raised HbA1c (above your individual target) indicates that average blood glucose has been persistently elevated. Over time, this increases the risk of serious diabetes-related complications, including:

• Microvascular complications: diabetic retinopathy (eye disease), nephropathy (kidney damage), and peripheral neuropathy (nerve damage)

• Macrovascular complications: increased risk of heart attack, stroke, and peripheral arterial disease

In practice, a single elevated result does not automatically trigger an immediate change in medication. Your GP or diabetes team will first explore potential contributing factors — such as recent illness, changes in diet, reduced physical activity, use of corticosteroids, or difficulties with medication adherence — before adjusting the management plan. NICE guidance (NG28) recommends a stepwise approach to intensifying treatment in type 2 diabetes, moving from lifestyle modification through oral agents to injectable therapies where necessary. Where there is a marked rise in HbA1c alongside symptoms such as significant weight loss, excessive thirst, or ketonuria, an expedited clinical review is warranted.

A low HbA1c can sometimes be achieved at the expense of recurrent hypoglycaemia (low blood sugar), particularly in people taking insulin or a sulphonylurea. Recurrent hypoglycaemia carries its own risks, including cardiovascular events, falls, and impaired awareness of future episodes. It is important to note that 48 mmol/mol is the NICE-recommended target for adults with type 1 diabetes — a result at or near this level is not inherently concerning unless it is accompanied by frequent hypoglycaemia. In such cases, the clinical team may consider relaxing the target slightly, especially in older adults or those with frailty, in line with NICE and NHS England guidance on individualised care. Where HbA1c appears discordant with symptoms or day-to-day glucose readings, CGM or flash glucose monitoring — providing time-in-range and hypoglycaemia burden data — can complement HbA1c and guide management.

When to seek urgent help: Contact your GP or diabetes nurse promptly if you notice symptoms such as persistent thirst, frequent urination, or unexplained fatigue, as these may indicate poorly controlled blood glucose. Seek same-day urgent medical attention or call 999 if you or someone else experiences symptoms of diabetic ketoacidosis (DKA) — including nausea or vomiting, abdominal pain, rapid or deep breathing, confusion, or the smell of ketones on the breath — or severe hypoglycaemia such as seizure or loss of consciousness. For other acute concerns, call NHS 111 for advice.

How to Manage Your HbA1c Levels with NHS Support

Effective HbA1c management combines dietary changes, regular physical activity, weight management, and medication optimisation guided by NICE NG28. NHS programmes such as DESMOND, DAFNE, and structured annual diabetes reviews support long-term glucose control.

Managing HbA1c effectively is rarely about a single intervention — it involves a combination of lifestyle measures, medication optimisation, and regular engagement with NHS diabetes services. Even modest improvements in HbA1c can meaningfully reduce the risk of long-term complications.

Lifestyle modifications remain the foundation of diabetes management at every stage:

• Diet: A balanced diet low in refined carbohydrates and added sugars, and rich in fibre, vegetables, and lean protein, can have a significant impact on blood glucose levels. Structured education programmes such as DESMOND or X-PERT (for type 2 diabetes) and DAFNE (for type 1 diabetes) provide evidence-based dietary and self-management support and are available through NHS referral.

• Physical activity: Regular aerobic exercise — at least 150 minutes of moderate-intensity activity per week — improves insulin sensitivity and helps lower HbA1c. UK Chief Medical Officers' guidelines also recommend muscle-strengthening activities on at least two days per week and reducing prolonged sedentary time.

• Weight management: In type 2 diabetes, even a 5–10% reduction in body weight can produce clinically meaningful improvements in HbA1c. The NHS Low Calorie Diet Programme offers structured support for eligible individuals (typically those with a recent type 2 diabetes diagnosis and a BMI above a specified threshold); availability depends on local commissioning — your GP can advise whether you qualify.

• NHS Diabetes Prevention Programme (NHS DPP): This programme is designed for adults identified with non-diabetic hyperglycaemia (42–47 mmol/mol) who are at high risk of developing type 2 diabetes, rather than for those with an established diagnosis.

Medication management is equally important. If lifestyle changes alone are insufficient, your GP or diabetes team will review your current regimen in line with NICE NG28. Metformin remains a standard first-line option for many adults with type 2 diabetes, unless contraindicated. However, for people with established cardiovascular disease, heart failure, or chronic kidney disease, SGLT-2 inhibitors may be recommended as a first-line or early addition to treatment, irrespective of metformin use, given their evidence-based cardiorenal benefits. Additional agents — including GLP-1 receptor agonists or DPP-4 inhibitors — are selected in a stepwise, individualised fashion based on clinical need, cardiovascular risk, and renal function.

For people with type 1 diabetes, insulin therapy is essential, and the type, dose, and timing may be adjusted in response to HbA1c trends. Continuous glucose monitoring (CGM) is recommended by NICE for all adults with type 1 diabetes and is available on the NHS; some adults with type 2 diabetes who use insulin may also meet criteria for NHS-funded CGM — your diabetes team can advise.

If you are taking any diabetes medication and experience a suspected side effect, you can report it directly to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Finally, regular NHS diabetes reviews are essential for catching problems early. Annual checks typically include HbA1c, blood pressure, lipid profile, kidney function (eGFR and urine albumin-to-creatinine ratio), retinal screening, foot examination (pulses and sensation), and review of vaccinations such as influenza. If you have concerns about your HbA1c or feel your diabetes is not well controlled, contact your GP surgery or diabetes specialist nurse for a review.

Frequently Asked Questions